Rein Therapeutics Inc. (RNTX) return on equity (ROE)

Return on equity · fiscal 2024
-669.9%

Rein Therapeutics Inc. (RNTX) earned a return on equity of -669.9% in fiscal 2024 (the year ended December 31, 2024). That is 441.5 percentage points lower than the -228.4% of fiscal 2023. Figures as of 18 Nov 2026, 00:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2024
-669.9%
Change on fiscal 2023
−441.5 pts
Highest on record
-47.3%fiscal 2017
Lowest on record
-669.9%fiscal 2024
Fiscal years on record
82017–2024

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Rein Therapeutics Inc. return on equity (ROE), in more detail

Across the 8 fiscal years on record (2017–2024), the highest was -47.3% in fiscal 2017 and the lowest -669.9% in fiscal 2024. The fiscal 2024 figure is no higher than in any of the 7 earlier fiscal years on record, whose median is -161.0%.

History · 8 fiscal years

Return on equity by fiscal year

Rein Therapeutics Inc. return on equity (ROE), year by year

Rein Therapeutics Inc. (RNTX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2024-669.9% 441.5 pts down
2023-228.4% 81.7 pts down
2022-146.7% 87.2 pts down
2021-59.6% 165.1 pts up
2020-224.7% 41.7 pts down
2019-183.0% 22.1 pts down
2018-161.0% 113.7 pts down
2017-47.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on RNTX

Rein Therapeutics Inc., figure by figure

Rein Therapeutics Inc. (RNTX) overview: price, valuation and scorecard

Rein Therapeutics Inc. return on equity (ROE): questions and answers

What is Rein Therapeutics Inc.'s return on equity?

Rein Therapeutics Inc. (RNTX) earned a return on equity of -669.9% in fiscal 2024 (the year ended December 31, 2024). That is 441.5 percentage points lower than the -228.4% of fiscal 2023.

Is Rein Therapeutics Inc.'s return on equity high or low compared with its own history?

The fiscal 2024 figure is no higher than in any of the 7 earlier fiscal years on record, whose median is -161.0%.

What are the highest and lowest return on equity figures on record for Rein Therapeutics Inc.?

Across the 8 fiscal years on record (2017–2024), the highest was -47.3% in fiscal 2017 and the lowest -669.9% in fiscal 2024.

How is Rein Therapeutics Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Rein Therapeutics Inc. (RNTX) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/RNTX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.